New tool helps decide what drugs to include in health care formularies

A new tool that could provide a useful framework for deciding what medicines to include in drug formularies is presented in this week's PLoS Medicine by the experts from Harvard Medical School and the University of Illinois at Chicago who developed it.

The experts, led by Gordon Schiff, say: "Formularies and committees that oversee them are present in some form in virtually every US hospital and outpatient drug plan and are highly visible components of public benefits in many countries. Thus decisions made by these committees directly or indirectly impact every prescriber, , and patient."

Although considerable attention has been devoted to their role in cost containment, the authors argue that "formularies' role in guiding rational remains underdeveloped and could be improved by a more standardized critical evaluation of drugs proposed for formulary placement."

So in a joint project, the authors developed a tool consisting of checklist of 48 questions for evaluating drugs to be considered for inclusion in the formulary related to the evidence of need, efficacy, , misuse potential, cost issues, and decision-making process.

The authors say: "The checklist can facilitate more standardized and critical scrutiny of the evidence and therapeutic alternatives. It can educate new committee members, guide discussions of drugs proposed for formulary addition, and be used to evaluate the quality of committee decision making."

The authors conclude: "we offer the tool for a broader audience to use and test. We hope that it will prove useful in improving the quality of formulary decision making and stimulating debate related to critical questions that need to be asked, highlighting essential data needed to more safely prescribe drugs."

More information: Schiff GD, Galanter WL, Duhig J, Koronkowski MJ, Lodolce AE, et al. (2012) A Prescription for Improving Drug Formulary Decision Making. PLoS Med 9(5): e1001220. doi:10.1371/journal.pmed.1001220

add to favorites email to friend print save as pdf

Related Stories

Higher co-payments reduce use of antidepressants

Jun 07, 2008

As they struggle to contain skyrocketing medication costs, health plans across the U.S. have responded by implementing multi-tiered formularies requiring higher copayments for 'non-preferred' medications. New research from ...

US Medicaid drug lists cost more, deliver less

Jun 17, 2011

The U.S. Medicaid program is likely paying far more than necessary for medications and not offering patients the most effective ones available, by ignoring international evidence-based lists of safe and effective medications, ...

Recommended for you

Protalix signs supply deal with Brazilian govt

9 hours ago

Shares of Protalix BioTherapeutics Inc. jumped in premarket trading Wednesday after the drug developer announced a deal that requires the Brazilian government to buy at least $280 million of the company's Gaucher disease ...

EU fines pharma firms over generics delay (Update)

10 hours ago

(AP)—The European Union has fined Danish pharmaceuticals multinational Lundbeck and several other producers a combined 146 million euros ($195 million) for delaying the market entry of cheaper generic alternatives ...

Investigational drug improves sleep disorder among the blind

Jun 17, 2013

An investigational new drug significantly improved a common and debilitating circadian rhythm sleep disorder that frequently affects people who are completely blind, a multicenter study finds. The results were presented Monday ...

User comments

More news stories

One in four stroke patients suffer PTSD

One in four people who survive a stroke or transient ischemic attack (TIA) suffer from symptoms of post-traumatic stress disorder (PTSD) within the first year post-event, and one in nine experience chronic PTSD more than ...